Search results
Showing 226 to 240 of 339 results for eq-5d
Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) for treating metastatic colorectal cancer after 2 systemic treatments in adults.
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088)
Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over.
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE